A new online prognostic model may help men with luminal early breast cancer avoid unnecessary chemotherapy. The tool, validated in over 3,000 patients from the U.S. and China, uses machine learning to predict 5-year survival and stratify risk.
Low-risk patients showed no survival benefit from chemotherapy, while high-risk individuals had a significant advantage. The model supports individualized treatment decisions, reducing exposure to aggressive therapy for those unlikely to benefit.
Researchers say the tool could transform perioperative care for male breast cancer patients, offering a more precise clinical approach.